TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* informed consent~* age 18-35 years~* known allergy on house-dust mite~* GINA 0-1~Exclusion Criteria:~* anamnestic incompatibility to parts of autovaccine~* asthma \> GINA I°~* chronic disease conditions or infections~* pregnancy~* inhalative or systemic steroid use~* any immunosuppressive therapy~* intake of any other probiotic medication (e.g. E.coli nissle 1917)~* participation in any other study at the same time~* substance abuse~* Incapability of understanding the study's purpose and performance~* smoker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): house dust mite allergics will undergo autovaccine immunization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Tendoactive, Eccentric Training, and the Combination of Both as a Treatment of Achilles Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from a gradually evolving painful condition in the Achilles tendon located at the midportion for at least 3 months (Diagnosis based on clinical examination showing a painful thickening of the Achilles tendon located at a level of 2 to 6cm above the tendon insertion, and confirmed by ultrasonography: local thickening of the tendon, irregular tendon structure with hypoechoic areas and irregular fiber orientation).~* Men and non-pregnant women aged 18-70 years~* Be informed of the nature of the study and provide written informed consent.~Exclusion Criteria:~* Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)~* Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpable gap)~* Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)~* Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)~* Clinical suspicion of peroneal subluxation~* Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.~* Condition that prevents the patients from executing an active exercise programme~* Patient has already performed eccentric exercises, according to the schedule of Alfredson et al (12 weeks)~* Patient has already received an injection of PRP for this injury~* Patient does not wish, for whatever reason, to undergo one of the two treatments~* Known presence of a pregnancy~* Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tendoactive (Type: EXPERIMENTAL): Tendoactive dosage: 3 capsules per day
- Eccentric training (Type: ACTIVE_COMPARATOR): Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
- Tendoactive and eccentric training (Type: ACTIVE_COMPARATOR): Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Two Imiquimod Cream 5%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp~* Women either must be 1 year post-menopausal, surgically sterile, or agree to use a medically accepted form or birth control~* Free of any systemic or dermatological disorder~* Any skin type or race, providing the skin pigmentation will allow discernment of erythema~Exclusion Criteria:~* Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)~* History of cutaneous hyperreactivity or facial irritation to topical products~* Engaging in activities involving excessive or prolonged exposure to sunlight~* Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry~* Currently using or have used systemic steroids 2 months prior to study~* Currently using or have used on the treatment area over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization~* Pregnant or nursing mothers~* History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation~* Taking immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imiquimod 5% Taro (Type: EXPERIMENTAL): Imiquimod 5% manufactured by Taro applied for 16 weeks
- Aldara - Imiquimod 5% (Type: ACTIVE_COMPARATOR): Aldara, Imiquimod 5% applied for 16 weeks
- Vehicle (Type: PLACEBO_COMPARATOR): Imiquimod vehicle applied for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~1. Male and female outpatients~2. age 18-30~3. diagnosis of ADHD by DSM-IV, per clinical evaluation and confirmed by structured interview~4. likeability response (\> 5) on Question #2 of the DRQ-S after an initial test dose of 60 mg of IR MPH.~5. Baseline ADHD severity of \> 20 on the Adult ADHD Investigator System Report Scale (AISRS)~6. Able to participate in blood draws and to swallow pills.~7. Subjects must be considered reliable reporters, must understand the nature of the study and must sign an informed consent document~Exclusion~1. Any current (last month), non-ADHD Axis I psychiatric conditions~2. Ham-D \> 16, BDI \> 19, or Ham-A \> 21~3. Any clinically significant chronic medical condition~4. any cardiovascular disease or hypertension~5. Clinically significant abnormal baseline laboratory values~6. I.Q. \< 80)~7. Organic brain disorders~8. Seizures or tics~9. Pregnant or nursing females~10. Clinically unstable psychiatric conditions (i.e. suicidal behaviors, psychosis)~11. Current or recent (within the past year) substance abuse/dependence~12. patients on other psychotropics~13. Current or prior adequate treatment with MPH~14. known hypersensitivity to methylphenidate~15. Current opioid use (by history and urine screen) or potential need for opioid analgesics during the study~16. acute hepatitis or liver failure (baseline blood tests).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): Arm 1: Naltrexone + SODAS MPH
- Placebo (Type: PLACEBO_COMPARATOR): Arm 2: Placebo + SODAS MPH

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female participants ≥ 55 years of age~2. Newly diagnosed, histologically confirmed de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or CMML (Chronic myelomonocytic leukemia)~3. First complete remission (CR)/ complete remission with incomplete blood count recovery (CRi) with induction therapy with intensive chemotherapy with or without consolidation therapy within 4 months (+/- 7 days of achieving CR or CRi)~4. Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, 2, 3~Key Inclusion Criteria in the Extended Phase of the study:~At the Investigator's discretion and with approval of the sponsor, participants meeting all of the following eligibility criteria are eligible to enter the extension phase:~1. All participants randomized into the oral azacitidine or placebo arm and are continuing in either the treatment phase or follow-up phase of the CC-486-AML-001 study;~   * Participants randomized to oral azacitidine treatment arm and continuing in the treatment phase demonstrating clinical benefit as assessed by the investigator are eligible to receive oral azacitidine in the extension phase (EP);~  * Participants randomized into placebo arm of the study will not receive oral azacitidine in the EP, but will be followed for survival in the EP;~  * Participants currently in the follow-up phase will continue to be followed for survival in the EP;~2. Participants who have signed the informed consent for the EP of the study;~3. Participants who do not meet any of the criteria for study discontinuation~Key Exclusion Criteria:~1. AML with inversion (inv)(16), translocation = t(8;21), t(16;16), t(15;17), or t(9;22) or molecular evidence of such translocations~2. Prior bone marrow or stem cell transplantation~3. Have achieved CR/CRi following therapy with hypomethylating agents~4. Diagnosis of malignant disease within the previous 12 months~5. Proven central nervous system (CNS) leukemia

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral Azacitidine (Type: EXPERIMENTAL): 300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
- Placebo (Type: PLACEBO_COMPARATOR): Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All vaccinees must be Hong Kong residents aged between 6 and 17.~Exclusion Criteria:~* Vaccinees should not be allergic or hypersensitive to the active substances or components (eggs, chicken proteins, formaldehyde, neomycin, etc.) used in the vaccines or where vaccination is otherwise contraindicated. Subjects should not have an underlying immunocompromised condition or be receiving immunosuppressive agents.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Influenza vaccine
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Type II diabetes that are on stable treatment with hypoglycemic agents~* Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mmHg but \<200 mmHg and a MSDBP less than or equal to 114 mmHg following a 3 to 4-week single-blind placebo run-in period~* The difference in MSSBP between Visits 3 and 4 or between Visits 4 and 4X must be less than or equal to 10 mmHg~* Patients with a mean daytime (8AM - 4PM) SBP \> 130 mmHg and less than or equal to 199 mmHg and a mean daytime DBP less than or equal to 114 as measured by an ambulatory blood pressure monitoring device (ABPM) following placebo run-in period~* If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study~Exclusion Criteria:~* History of stroke or transient ischemic attack (TIA) within the last one year~* History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months~* Presence of overt proteinuria at screening~* Severe hypertension (DBP greater than or equal to 115 mmHg or SBP greater than or equal to 200 mmHg)~* Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome~* Type I or Type II diabetes requiring insulin~* Evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease~* Presence of heart block greater than first degree sinoatrial block, Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial fibrillation, or Atrial Flutter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Probiotics in Enteral Feeding in Critically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to intensive care unit~* Expected stay of more than 48 hours~* On enteral feeding~* Consent obtained from patient/relative~Exclusion Criteria:~* Patients on immuno-suppressive drugs~* Patients with hematological diseases~* Pregnant females~* Do not consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients on enteral feeding in intensive care units are administered a placebo
- Probiotics (Type: ACTIVE_COMPARATOR): Patients on enteral feeding in intensive care unit are given a probiotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diabetes mellitus (type 1 or 2) (for the patients) or absence of diabetes mellitus and other carbohydrates metabolism alterations (for the non diabetic controls)~* Age 20-65 years;~* Both genders;~* Informed consent.~Exclusion criteria:~* Age \<20 or \>65 years;~* Pregnancy or lactation \*~* Recent surgery or trauma;~* Recent acute diseases (within 2 months from study entry);~* Immune diseases (except from type I diabetes and autoimmune thyroiditis);~* Chronic infectious diseases;~* Hematologic malignancies either past or present;~* Solid tumor known or strongly suspected;~* Leukocytosis, leukopenia, or thrombocytopenia;~* Solid organ transplant or immunosuppression;~* Alteration of hepatic function (transaminases \>2 ULN);~* Severe chronic diabetic micro- or macroangiopathy~* HbA1c \>11%.~* Deficit in renal function (eGFR\<50 ml/m2);~* Significant abnormalities of the peripheral lymphocyte immunophenotype;~* Known hypersensitivity to Mozobil or its excipients;~* Refusal / inability to provide informed consent.~  * women with childbearing potential can participate to this trial just if are using effective oral contraception; a negative pregnancy test is required before study entry). Women will be asked to continue oral contraception for 3 months after Mozobil administration.~All antidiabetic medications are allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Stem cell mobilization in diabetic patients (Type: EXPERIMENTAL): Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
- Stem cell mobilization in non diabetic subjects (Type: EXPERIMENTAL): Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults or adolescents (age\>13 years) and weight\> 34kg, either gender~* Disease definition: Anticipated or documented prolonged neutropenia (ANC\<500/mm3 2) Eastern Cooperative Oncology Group (ECOG) performance score of less than 3.~* Female subjects of childbearing age must be using a medically accepted method of birth control before beginning study-drug treatment and agree to continue its use during the study or be surgically sterilized (eg, hysterectomy or tubal ligation).~* Female subjects of childbearing potential must have a negative serum pregnancy test (beta-hcG) at Baseline or within 72 hours before the start of the study drug.~Exclusion Criteria:~* Female subjects who are pregnant, intend to become pregnant, or are nursing.~* Excluded prior treatments: Subjects previously treated with AMB, FLZ, or ITZ for proven or probable IFI within 30 days of enrollment.~* Excluded treatments prior to specific study phases: Subjects who have taken the following drugs: those known to interact with azoles and that may lead to life-threatening side effects.~* Subjects who have used any investigational drugs or biologic agents other than their chemotherapy regimens within 30 days of study entry.~* Subjects who are participating in any other blinded clinical study within 30 days of study entry.~* Subjects with renal insufficiency (estimated creatinine clearance less than 20 mL/minute at Baseline or likely to require dialysis during the study).~* Subjects having an ECG with a prolonged QTc interval by manual reading: QTc greater than 450 msec for men and greater than 470 msec for women.~* Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN), or a total bilirubin level greater than 3 times the ULN.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Age ≥ 18 years, able and willing to give signed and informed consent.~2. Patient with histologically proven recurrent de novo GBM:~   1. After at least a first-line standard of care (maximal safe resection, if feasible, radiation with temozolomide \[TMZ\], then TMZ);~  2. Any recurrence;~  3. Bevacizumab-naïve.\*~3. Patient eligible for carboplatin-based chemotherapy.~4. Patient eligible for a surgical resection.~5. Maximal tumor diameter at inclusion (pre surgery) ≤ 70 mm in T1wMRI.~6. Patients should be stable, without evidence of a midline shift, significant peritumoral edema, or rapid progression of clinical symptoms.~7. Karnofsky performance status ≥ 70.~8. Patient receiving prednisone dose ≤ 40 mg (dexamethasone ≤ 6 mg) for at least 7 days.~Key Exclusion Criteria:~1. Multifocal tumor (unless all localized in a 70 mm diameter area).~2. Patients at risk of surgery site infection (2 or more previous craniotomies, neurosurgery within the last 3 months, poor skin condition, and/or previously infected surgical field).~3. Posterior fossa tumor.~4. Uncontrolled epilepsy.~5. Patients with evidence of uncontrolled intracranial pressure.~6. Patients with known intracranial aneurism or having presented intra-tumor spontaneous hemorrhage.~7. Patients with coils, clips, shunts, intravascular stents, and/or unremovable wafer, non resorbable dura substitute, or reservoirs.~8. Patients with medical need to continue antiplatelet therapy.~9. Patients with known or suspected active or chronic infections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoCloud-9 Ultrasound + Carboplatin (Type: EXPERIMENTAL): SonoCloud-9 Carboplatin: 6 cycles (every 4 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete